Press Releases

April 9, 2020 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine

GMP-Manufactured Batch to be Delivered in June 2020 Human Dosing Expected to Begin in Summer 2020 SAN DIEGO , April 09, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and

PDF Version
March 27, 2020 at 7:00 AM EDT

Summary Toggle Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System

Data will help Arcturus learn more quickly about LUNAR-COV19 efficacy and safety profile SAN DIEGO , March 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines and vaccines company, today provided details about the Company’s strategy to

PDF Version
March 11, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results

IND Filed for Flagship Program ARCT-810 Coronavirus Vaccine Program Initiated Investor Conference Call at 4:30 pm ET Today SAN DIEGO, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery,

PDF Version
March 4, 2020 at 7:30 AM EST

Summary Toggle Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology

Collaboration seeks to conduct pre-clinical testing followed by first-in-human clinical trials SAN DIEGO and SINGAPORE , March 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company, and Duke-NUS Medical School (Duke-NUS), a

PDF Version
February 24, 2020 at 7:30 AM EST

Summary Toggle Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11

SAN DIEGO , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview and

PDF Version
February 19, 2020 at 7:30 AM EST

Summary Toggle Arcturus Therapeutics to Present at Two Investor Conferences in March

SAN DIEGO , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne , Chief Executive Officer,

PDF Version
January 8, 2020 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

SAN DIEGO , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced the appointment of Steve Hughes , M.D., as

PDF Version
November 7, 2019 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“ Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today reported its financial results

PDF Version
November 7, 2019 at 7:30 AM EST

Summary Toggle Arcturus Therapeutics Expands Platform with STARR™ Technology

SAN DIEGO , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT, the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that the Company is expanding its platform to

PDF Version
November 4, 2019 at 7:30 AM EST

Summary Toggle Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th

SAN DIEGO , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview and financial

PDF Version